Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure: Interaction With Tumor Necrosis Factor α -308 G/A Polymorphism.
BACKGROUND
Apolipoprotein A1 (ApoA1), a major constituent of high-density lipoprotein (HDL), has antiinflammatory and antioxidative properties and plays a prognostic role in chronic heart failure (CHF). Despite increased tumor necrosis factor α (TNFα) levels being linked to worse outcome of HF, the results are ambiguous about the association of functionally active 308 promoter polymorphism of the TNFα gene. The aims of our study were to investigate the association of ApoA1 and TNFα levels with mortality and to evaluate potential interaction between these factors and TNFα -308 polymorphism.


METHODS
Together with several parameters ApoA1, TNFα levels and TNFα-308 polymorphism were determined in a cohort of 195 patients with CHF who were followed for 5 years.


RESULTS
Low ApoA1 and high TNFα levels were associated with more severe disease, and ApoA1 showed the strongest relationship with HDL, total cholesterol, C-reactive protein, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). TNFα -308 A carriers had significantly higher ApoA1 levels than wild-type (GG) patients (1.41 ± 0.268 vs 1.29 ± 0.324 g/L; P = .007), whereas levels of TNFα were the same in these groups. Decreased ApoA1 levels were significant predictors of 5-year mortality (NT-proBNP-adjusted HR for 1 decile decrease in ApoA1 level was 1.10 (P = .011). Interaction was found between the ApoA1 level and TNFα -308 polymorphism, because in patients with GG haplotype the adverse effect of low ApoA1 level on survival was more prevalent.


CONCLUSIONS
Lower ApoA1 levels were strongly associated with adverse outcome in CHF patients in a TNFα -308 polymorphism dependent manner. These observations support the complex involvement of malnutrition and inflammation in the pathogenesis of CHF.
IIIrd Department of Internal Medicine, Semmelweis University, Budapest, Hungary. Electronic address: tgombos@gmail.com.
Tímea
T
Gombos
IIIrd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Zsolt
Z
Förhécz
IIIrd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Zoltán
Z
Pozsonyi
IIIrd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Lívia
L
Jánoskuti
IIIrd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Zoltán
Z
Prohászka
IIIrd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
István
I
Karádi
D000368:Aged; D016632:Apolipoprotein A-I / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005786:Gene Expression Regulation; D006333:Heart Failure / Q000401:mortality* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D011379:Prognosis; D011401:Promoter Regions, Genetic; D016016:Proportional Hazards Models; D012042:Registries; D018570:Risk Assessment; D017741:Survivors / Q000706:statistics & numerical data*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
D016632:Apolipoprotein A-I; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha
Apolipoprotein A1 (ApoA1); TNFα −308 G/A promoter polymorphisms; Tumor necrosis factor alpha (TNFα); cholesterol paradox; chronic heart failure (CHF)